Correlation Between Karyopharm Therapeutics and Sage Therapeutic

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Sage Therapeutic at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Sage Therapeutic into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Karyopharm Therapeutics and Sage Therapeutic, you can compare the effects of market volatilities on Karyopharm Therapeutics and Sage Therapeutic and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Sage Therapeutic. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Sage Therapeutic.

Diversification Opportunities for Karyopharm Therapeutics and Sage Therapeutic

0.3
  Correlation Coefficient

Weak diversification

The 3 months correlation between Karyopharm and Sage is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Sage Therapeutic in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sage Therapeutic and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Sage Therapeutic. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sage Therapeutic has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Sage Therapeutic go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Sage Therapeutic

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Sage Therapeutic. But the stock apears to be less risky and, when comparing its historical volatility, Karyopharm Therapeutics is 2.01 times less risky than Sage Therapeutic. The stock trades about -0.71 of its potential returns per unit of risk. The Sage Therapeutic is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  528.00  in Sage Therapeutic on September 26, 2024 and sell it today you would earn a total of  20.00  from holding Sage Therapeutic or generate 3.79% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Karyopharm Therapeutics  vs.  Sage Therapeutic

 Performance 
       Timeline  
Karyopharm Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.
Sage Therapeutic 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sage Therapeutic has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Karyopharm Therapeutics and Sage Therapeutic Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Karyopharm Therapeutics and Sage Therapeutic

The main advantage of trading using opposite Karyopharm Therapeutics and Sage Therapeutic positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Sage Therapeutic can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sage Therapeutic will offset losses from the drop in Sage Therapeutic's long position.
The idea behind Karyopharm Therapeutics and Sage Therapeutic pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Other Complementary Tools

Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Valuation
Check real value of public entities based on technical and fundamental data
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account